The company resolved a lawsuit with the Centers for Medicare & Medicaid Services, resulting in a one-time, non-cash benefit of $246M. This removes a significant liability and is expected to improve the gross-to-net margin for its Opzelura product, potentially freeing up capital and management focus for other initiatives.
Filing excerpt
Incyte Corporation (the “Company”) today announced that it has reached an agreement with the Centers for Medicare & Medicaid Services (“CMS”) to resolve the Company’s litigation related to the application of Medicaid rebate rules to Opzelura® (ruxolitinib) cream.
What this signalsFilings often name leadership changes, deals and spending plans.
sec-8klitigationMaterialGet every 8-K signal for Incyte and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Incyte this week?”
The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/f02e2eff-d8fe-4512-9261-3d2b74eb4e7c returns this record as JSON. POST /v1/companies/enrich returns every signal for incyte.com.
{
"signal_id": "f02e2eff-d8fe-4512-9261-3d2b74eb4e7c",
"signal_type": "sec-8k",
"signal_subtype": "litigationMaterial",
"detected_at": "2026-06-23T07:10:48.502+00:00",
"company": {
"name": "Incyte",
"domain": "incyte.com"
},
"data": {
"detail": "The company resolved a lawsuit with the Centers for Medicare & Medicaid Services, resulting in a one-time, non-cash benefit of $246M. This removes a significant liability and is expected to improve the gross-to-net margin for its Opzelura product, potentially freeing up capital and management focus for other initiatives.",
"metrics": {
"timeframe": "current_quarter",
"dollar_context": "one-time, non-cash benefit from reversal of previously established accrual balances",
"dollar_millions": 246
},
"summary": "Incyte to record $246M benefit after settling CMS litigation over Opzelura drug pricing",
"excerpts": "Incyte Corporation (the “Company”) today announced that it has reached an agreement with the Centers for Medicare & Medicaid Services (“CMS”) to resolve the Company’s litigation related to the application of Medicaid rebate rules to Opzelura® (ruxolitinib) cream.",
"relevance": 0.9,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/879169/000087916926000046/incy-20260622.htm",
"filing_date": "2026-06-22",
"filing_year": 2026,
"fiscal_year_end": "06/22",
"sales_relevance": "Legal tech opportunity",
"signal_category": "risk"
}
}
curl https://signals.autobound.ai/v1/signals/f02e2eff-d8fe-4512-9261-3d2b74eb4e7c \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"incyte.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.